• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Research and development

Clinical trials

Our world class studies take place mostly in remote settings

Home > Research and development

Clinical trials

Our world class studies take place mostly in remote settings

  • Clinical trials
  • Clinical trial protocol synopses

At DNDi, we work with research partners from around the world to evaluate new and improved medicines and treatment regimens in clinical trials. The evidence from these studies enables us to deliver better, more affordable treatments for the most neglected.

We conduct world-class clinical trials following Good Clinical Practice standards even in the most remote and rural areas. This involves infrastructure updates and training for clinical staff, often through regional disease-specific research networks supported by DNDi. We also screen and treat people for various diseases, regardless of whether they end up being included in our clinical trials.

Clinical Trial Synopses
Access Clinical Trial Data
Icon test tubes
in 8 diseases areas at 68 sites in 25 countries last year
0 clinical trials
Icon globe
disease-specific clinical research ‘platforms’ created in Africa, Asia, and Latin America
0
Icon people
patients enrolled in clinical trials at any given time
> 0

‘To ensure [our trials] were Good Clinical Practice compliant, we needed to strengthen capacities in terms of infrastructure and expertise. These improvements will be useful to the Congolese research community and should last for future studies.’

Dr Crispin Lumbala, former Director, National Sleeping Sickness Control Programme, DRC

Networked research groups build capacity and increase research quality

Since 2003, DNDi has supported the creation of five disease-specific clinical research ‘platforms’ that bring together key actors including health ministries, national disease control programmes, regulatory authorities, WHO, academia, civil society groups, and clinicians and other health professionals.

The platforms serve as ‘knowledge hubs’ that:

  • help identify patients’ needs and R&D gaps,
  • strengthen and sustain clinical research capacity,
  • facilitate access to new treatments, and
  • advocate for an enabling policy and regulatory environment for needs-driven R&D.
Chagas Clinical Research Platform logo

Chagas Platform

Chagas disease

learn more
Dengue Alliance logo

Dengue Alliance

Dengue

learn more
HAT Platform logo

HAT Platform

Sleeping sickness

learn more
LEAP Platform logo

LEAP Platform

Leishmaniasis

learn more

redeLEISH Network

Leishmaniasis

learn more

Clinical trial data transparency

DNDi recognizes the value to researchers in public health, and other actors, of sharing and disseminating our clinical data. Sharing responsibly can contribute to knowledge for the improvement of the lives of neglected patients whose needs are often overlooked as research priorities.

We are committed to sharing our clinical trial data in a way that respects participants in medical research and maximizes the benefits to participants and society, while minimizing any potential harm.

  • In 2017, we signed the World Health Organization’s Joint statement on public disclosure of results from clinical trials
  • You can read more about our commitment to data sharing in DNDi’s Policy on Sharing and Secondary Use of Human Subject Research Data.
  • Researchers who would like access to DNDi clinical data are requested to visit the website of our data-sharing partner, Vivli, to make a data request
  • If you have any inquiries about access to DNDi’s clinical study data, please write to  CTdata@dndi.org

 

Projects

DNDi is sponsoring or collaborating on clinical trials taking place across 5 continents and 8 disease areas.

Loading…
Clinical trials

Miltefosine + thermotherapy for cutaneous leishmaniasis

Combining existing treatments to improve patient outcomes. Preliminary results from our Phase II trial in Peru and Colombia showed better outcomes combining thermotherapy and miltefosine compared to treatment with thermotherapy alone. A Phase III study is ongoing in four countries in Latin America. 

Clinical trials

Acoziborole

A radical boost for sustainable elimination. This single-dose sleeping sickness treatment could be a true game-changer for people at risk of this deadly disease.

SEE ALL PROJECTS

Read, watch, share

Loading…
filter by
ALL
News
Press releases
Scientific articles
Stories
Videos
Scientific articles
29 Apr 2025

Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: A prospective, open-label, single-arm, Phase II–III, non-randomised study

The Lancet Global Health
Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Scientific articles
21 Apr 2025

A balancing act: Navigating the advantages and challenges of pioneering mycetoma treatment in Sudan – A landmark trial by the Mycetoma Research Center

PLOS Neglected Tropical Diseases
Scientific articles
17 Apr 2025

Accelerating access to paediatric medicines: lessons learned from the Global Accelerator for Paediatric Formulations, a WHO-hosted network

The Lancet Child & Adolescent Health
see ALL

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License